Atópiás dermatitisz (ekcéma): vizsgálatok itt: Kína
56 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- No phaseTaking peopleAssessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 80
- Run by
- Zhongda Hospital
See details and how to joinNCT07573735 - 1. fázisCsak meghívásosA Phase I Clinical Trial to Evaluate CU-10101 Unguent
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 64
- Run by
- Cutia Therapeutics(Wuxi)Co.,Ltd
See details and how to joinNCT06744569 - No phaseCsak meghívásosA Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 50
- Run by
- Xi Tan
See details and how to joinNCT06999941 - No phaseTaking peopleA Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 1000
- Run by
- Chengdu Kangnuoxing Biopharma,Inc.
See details and how to joinNCT07544862 - 1. fázisTaking peopleA Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 90
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07488065 - 1. fázisNot yet taking people in KínaA Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 16
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07549984 - 3. fázisNot yet taking people in KínaA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
- Where
- Shenyang
- Életkor
- 12 év to 17 év
- People
- 180
- Run by
- Shanghai Mabgeek Biotech.Co.Ltd
See details and how to joinNCT07540442 - 2. fázisTaking peopleA Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 75
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07211542 - 2. fázisTaking peopleA Clinical Study to Evaluate SM17 for Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 200
- Run by
- SinoMab BioScience Ltd
See details and how to joinNCT07445919 - 2. fázisNot yet taking people in KínaA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
- Where
- Beijing, Binzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Jinan, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suzhou, Tangshan, Tianjin, Wuhan, Xi'an, Yinchuan, Zhengzhou, Zhenjiang
- Életkor
- 18 év to 75 év
- People
- 160
- Run by
- Dermavon Holdings Limited
See details and how to joinNCT07465120 - 2. fázisTaking peopleA Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07399067 - 2. fázisTaking peopleA Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 111
- Run by
- Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT07193589 - 3. fázisTaking peopleEvaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
- Where
- Beijing, Jinhua, Nanchang
- Életkor
- 12 év to 17 év
- People
- 180
- Run by
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07042126 - 2. fázisTaking peopleA Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 246
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT07230483 - 3. fázisCsak meghívásosA Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 460
- Run by
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
See details and how to joinNCT07180511 - 3. fázisTaking peopleICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
- Where
- Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Handan, Hangzhou, Hefei, Hohhot, Jinan, Jingzhou, Jining, Jiujiang, Kunming, Liuzhou, Luoyang, Nanchang, Nanjing, Ningbo, Qingdao, Sanmenxia, Shanghai, Shaoguan, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xi’an, Yancheng, Yiwu, Yuncheng, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 552
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT06775860 - 3. fázisTaking peopleEfficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
- Where
- Shenyang
- Életkor
- 18 év to 75 év
- People
- 360
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06880276 - 2. fázisTaking peopleStudy of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 200
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT06947980 - 1. fázisTaking peopleA Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
- Where
- Suzhou
- Életkor
- 18 év to 65 év
- People
- 9
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07015762 - 3. fázisNot yet taking people in KínaA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
- Where
- Beijing
- Életkor
- 2 év to 12 év
- People
- 240
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT07106372 - 1. fázisTaking peopleA Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 102
- Run by
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
See details and how to joinNCT06946641 - 2. fázisNot yet taking people in KínaEvaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 120
- Run by
- Zhejiang Kanova Biopharmaceutical Co., LTD
See details and how to joinNCT07054736 - No phaseTaking peopleA Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 76
- Run by
- ChinaNorm
See details and how to joinNCT07022288 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
- Where
- Shenyang
- Életkor
- 12 év to 75 év
- People
- 472
- Run by
- Prime Gene Therapeutics Co., Ltd.
See details and how to joinNCT06587685 - 3. fázisNot yet taking people in KínaStudy of Stapokibatrt in Children Subjects With Atopic Dermatitis
- Where
- Beijing
- Életkor
- 2 év to 11 év
- People
- 240
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT06956196